See my note from June 29th
LNTH - following the prediction(s)
Will rise above 6 dollars this year and over the next 1-2 years will hit 10 dollars - fair price
for this company in a growing cardiac niche.
It is in a specialty cardiology field - in a growing market.
Should continue to increase in price with increase in earnings.
The products are used in most major cardiac centers.
Also a possible takeover candidate.
I expect the stock to reach 10 dollars within 2 years
In the next 6-12 months..this stock will be over 150.
I expect another 2:1 split later this year.
Once TAVR is approved for average risk individuals - the procedure will become the standard
for Aortic valve replacement.